TransCode Therapeutics, Inc. (RNAZ)
NASDAQ: RNAZ · Real-Time Price · USD
0.4320
+0.0320 (8.00%)
Apr 25, 2025, 12:11 PM EDT - Market open

TransCode Therapeutics Cash Flow Statement

Millions USD. Fiscal year is Jan - Dec.
Fiscal Year
FY 2024 FY 2023 FY 2022 FY 2021 FY 2020 2018 - 2019
Period Ending
Dec '24 Dec '23 Dec '22 Dec '21 Dec '20 2018 - 2019
Net Income
-16.75-18.55-17.56-6.84-2.34
Upgrade
Depreciation & Amortization
0.530.520.10.04-
Upgrade
Loss (Gain) From Sale of Assets
---0-
Upgrade
Stock-Based Compensation
1.71.040.40.190.05
Upgrade
Other Operating Activities
1.54--0.911.5
Upgrade
Change in Accounts Payable
-0.34-1.31.842.290.19
Upgrade
Change in Unearned Revenue
-00.03-0.030.03-
Upgrade
Change in Other Net Operating Assets
-0.010.19-0.5-1.880.12
Upgrade
Operating Cash Flow
-13.34-18.07-15.76-5.27-0.49
Upgrade
Capital Expenditures
-0.02-0.04-0.1-0.25-
Upgrade
Sale of Property, Plant & Equipment
---0-
Upgrade
Investing Cash Flow
-0.02-0.04-0.1-0.25-
Upgrade
Long-Term Debt Issued
----1.19
Upgrade
Net Debt Issued (Repaid)
----1.19
Upgrade
Issuance of Common Stock
16.415.910.0126.38-
Upgrade
Other Financing Activities
----0.86-0.07
Upgrade
Financing Cash Flow
16.415.910.0125.521.12
Upgrade
Net Cash Flow
3.04-2.2-15.86200.62
Upgrade
Free Cash Flow
-13.36-18.11-15.86-5.52-0.49
Upgrade
Free Cash Flow Per Share
-37.51----
Upgrade
Cash Interest Paid
0.020.030.040.02-
Upgrade
Levered Free Cash Flow
-7.53-11.21-9.96-3.7-0.31
Upgrade
Unlevered Free Cash Flow
-7.51-11.17-9.94-3.64-0.07
Upgrade
Change in Net Working Capital
-0.060.56-1.31-0.23-0.34
Upgrade
Updated Nov 14, 2024. Source: S&P Global Market Intelligence. Standard template. Financial Sources.
SEC Filings: 10-K · 10-Q